stockrowNordicus Partners Corporation
NORD Healthcare Biotechnology
Nordicus Partners Corporation’s revenue for fiscal 2025 (year ended March 2025) was $5,000.00, up 100.0% from fiscal 2024.
- Revenue
- −99.6%
- EPS
- −85.7%
- Free cash flow
- +62.2%
Quarter to June 2026, against a year earlier
Follow NORD
Alert me
Nordicus Partners Corporation (NORD) Piotroski F-score
Nordicus Partners Corporation's Piotroski F-score for fiscal 2025 cannot be worked out: needs three fiscal years.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2018 | 8 | 6.00 |
| FY2017 | 2 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (8.05%) | — | Fail | 0 |
| Positive operating cash flow | (1.28m) | (258.90k) | Fail | 0 |
| Rising return on assets | (8.05%) | — | n/a | — |
| Cash flow above net income | 1.62m | 39.30k | Pass | 1 |
| Falling long-term leverage | 0.00 | — | n/a | — |
| Rising current ratio | 0.05 | 1.89 | Fail | 0 |
| No new shares issued | 9,205,000 | 1,035,000 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.00 | — | n/a | — |
| Piotroski F-score | n/a — needs three fiscal years | — | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| COYA Coya Therapeutics, Inc. compare | 3 |
| CRBP Corbus Pharmaceuticals Holdings, Inc. compare | 3 |
| NTRB Nutriband Inc. compare | 3 |
| CNXU Conexeu Sciences Inc. compare | — |
| OKYO OKYO Pharma Limited Sponsored ADR compare | — |
| NORD Nordicus Partners Corporation | — |
| MAIA MAIA Biotechnology, Inc. compare | — |
| ACRV Acrivon Therapeutics, Inc. compare | — |
| MNOV MediciNova, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover